Sage Journals: Discover world-class research

Retricted access

Research article

First published 2020-04

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia

Padmakumar Narayanan, Brian R. Curtis, Lijiang Shen [...]

Nucleic Acid Therapeutics

Open access

Research article

First published 2020-06

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen,an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

Rosie Z. Yu, Jon W. Collins, Shannon Hall [...]

Nucleic Acid Therapeutics

Retricted access

Research article

First published 2020-10

Immunogenicity Assessment of Inotersen,a 2′- O -(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics,Pharmacodynamics,and Safety

Rosie Z. Yu, Yanfeng Wang, Dan A. Norris [...]

Nucleic Acid Therapeutics

Open access

Review article

First published 2025

Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials

Maha Sajjad, Rabia Ashraf, Riya Bhagwan [...]

Therapeutic Advances in Cardiovascular Disease

Retricted access

Review article

First published 2026

Oligonucleotides: Evolution of Carcinogenicity and Risk Assessment Strategy

Tae-Won Kim

Toxicologic Pathology

Open access

Review article

First published 2021

Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’

Matthew J. Jennings, Angela Lochmüller, Antonio Atalaia [...]

Journal of Neuromuscular Diseases

Retricted access

Review article

First published 2021-12

Transthyretin Amyloid Cardiomyopathy—Current and Future Therapies

Jankhna D. Yadav, Harjot Othee, Kelly A. Chan [...]

Annals of Pharmacotherapy

Search results

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen,an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

Immunogenicity Assessment of Inotersen,a 2′- O -(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics,Pharmacodynamics,and Safety

Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials

Oligonucleotides: Evolution of Carcinogenicity and Risk Assessment Strategy

Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’

Transthyretin Amyloid Cardiomyopathy—Current and Future Therapies